Pawan Karanam, MDAssistant Professor AdjunctDownloadHi-Res PhotoCardsAppointmentsMedical Oncology and HematologyPrimaryContact Infopawan.karanam@yale.eduLearn moreabout Contact InfoAboutResearchNewsGet In TouchPawan KaranamAboutCopy LinkTitlesAssistant Professor AdjunctBiographyDr. Karanam completed his internal medicine residency at St. Vincent's Medical Center, and his Hematology/Oncology fellowship at Gundersen Health System.AppointmentsMedical Oncology and HematologyAssistant Professor AdjunctPrimaryOther Departments & OrganizationsInternal MedicineMedical Oncology & HematologyMedical Oncology and HematologyYale Cancer CenterEducation & TrainingMDOsmania Medical College (1990)ResearchCopy LinkClinical TrialsCurrent TrialsPhase 2 Study of Pembrolizumab and Brentuximab Vedotin in Subjects With Relapsed/Refractory CD30 Positive T-cell LymphomaHIC ID2000029793RoleSub InvestigatorPrimary Completion Date04/30/2028Recruiting ParticipantsLymphomaA Phase II/III Trial of Chemotherapy + Cetuximab vs Chemotherapy + Bevacizumab vs Atezolizumab + Bevacizumab Following Progression on Immune Checkpoint Inhibition in Recurrent/Metastatic Head and Neck CancersHIC ID2000032270RoleSub InvestigatorPrimary Completion Date12/15/2027Recruiting ParticipantsHead and Neck CancersRandomized Phase III Study of Combination Osimertinib (AZD9291) and Bevacizumab Versus Osimertinib (AZD9291) Alone as First-Line Treatment for Patients With Metastatic EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)HIC ID2000032879RoleSub InvestigatorPrimary Completion Date12/31/2026Recruiting ParticipantsLung CancerSIMCAP (Surgery in Metastatic Carcinoma of Prostate): Phase 2.5 Multi-Institution Randomized Prospective Clinical Trial Evaluating the Impact of Cytoreductive Radical Prostatectomy Combined With Best Systemic Therapy on Oncologic and Quality of Life Outcomes in Men With Newly Diagnosed Metastatic Prostate CancerHIC ID2000031290RoleSub InvestigatorPrimary Completion Date10/31/2025Recruiting ParticipantsGenderMaleAge18+ yearsProstate CancerNovel Combination of Belantamab Mafodotin and Elotuzumab to Enhance Therapeutic Efficacy in Multiple MyelomaHIC ID2000028918RoleSub InvestigatorPrimary Completion Date01/01/2025Recruiting ParticipantsMyelomaSee All Current Clinical TrialsNewsCopy LinkNewsMay 01, 2019Excellence, Innovation and Integration: Saint Francis Hospital Expands Cancer Care ServicesSource: Hartford Business JournalRead moreabout Excellence, Innovation and Integration: Saint Francis Hospital Expands Cancer Care ServicesGet In TouchCopy LinkContactsEmailpawan.karanam@yale.edu
Phase 2 Study of Pembrolizumab and Brentuximab Vedotin in Subjects With Relapsed/Refractory CD30 Positive T-cell LymphomaHIC ID2000029793RoleSub InvestigatorPrimary Completion Date04/30/2028Recruiting ParticipantsLymphoma
A Phase II/III Trial of Chemotherapy + Cetuximab vs Chemotherapy + Bevacizumab vs Atezolizumab + Bevacizumab Following Progression on Immune Checkpoint Inhibition in Recurrent/Metastatic Head and Neck CancersHIC ID2000032270RoleSub InvestigatorPrimary Completion Date12/15/2027Recruiting ParticipantsHead and Neck Cancers
Randomized Phase III Study of Combination Osimertinib (AZD9291) and Bevacizumab Versus Osimertinib (AZD9291) Alone as First-Line Treatment for Patients With Metastatic EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)HIC ID2000032879RoleSub InvestigatorPrimary Completion Date12/31/2026Recruiting ParticipantsLung Cancer
SIMCAP (Surgery in Metastatic Carcinoma of Prostate): Phase 2.5 Multi-Institution Randomized Prospective Clinical Trial Evaluating the Impact of Cytoreductive Radical Prostatectomy Combined With Best Systemic Therapy on Oncologic and Quality of Life Outcomes in Men With Newly Diagnosed Metastatic Prostate CancerHIC ID2000031290RoleSub InvestigatorPrimary Completion Date10/31/2025Recruiting ParticipantsGenderMaleAge18+ yearsProstate Cancer
Novel Combination of Belantamab Mafodotin and Elotuzumab to Enhance Therapeutic Efficacy in Multiple MyelomaHIC ID2000028918RoleSub InvestigatorPrimary Completion Date01/01/2025Recruiting ParticipantsMyeloma
May 01, 2019Excellence, Innovation and Integration: Saint Francis Hospital Expands Cancer Care ServicesSource: Hartford Business JournalRead moreabout Excellence, Innovation and Integration: Saint Francis Hospital Expands Cancer Care Services